300642.SZ
透景生命
SZSE · Healthcare · C 制造业 · CN
CNY 13.50
−1.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 371.5M | 363.8M | 436.8M | 542.8M | 716.0M |
| Cost of Revenue | 112.6M | 110.8M | 147.9M | 188.6M | 307.6M |
| Gross Profit | 259.0M | 253.1M | 288.9M | 354.2M | 408.4M |
| Operating Expenses | |||||
| R&D Expense | 60.1M | 58.5M | 65.7M | 77.7M | 79.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 44.0M | 43.1M | 31.5M | 31.5M | 37.2M |
| Selling & Marketing Expense | 122.1M | 116.4M | 130.7M | 175.5M | 194.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 231.5M | 220.3M | 225.5M | 286.2M | 305.7M |
| Cost and Expenses | 344.0M | 331.0M | 373.4M | 474.8M | 613.3M |
| Operating Income (EBIT) | (6.9M) | (2.1M) | 38.6M | 88.4M | 131.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (7.7M) | (2.9M) | 35.8M | 87.5M | 130.7M |
| Income Tax Expense | (1.5M) | (2.1M) | 7.4M | 2.8M | 6.9M |
| Bottom Line | |||||
| Net Income | (2.4M) | 3.6M | 34.5M | 89.4M | 124.8M |
| Earnings from Cont. Ops | (6.2M) | (824.4K) | 28.4M | 84.7M | 123.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2.4M) | 3.6M | 34.5M | 89.4M | 124.8M |
| Per Share | |||||
| Basic EPS | (CN¥0.02) | CN¥0.02 | CN¥0.21 | CN¥0.55 | CN¥0.77 |
| Diluted EPS | (CN¥0.02) | CN¥0.02 | CN¥0.21 | CN¥0.55 | CN¥0.77 |
| Revenue Per Share | CN¥2.33 | CN¥2.23 | CN¥2.69 | CN¥3.33 | CN¥4.40 |
| Shares | |||||
| Basic Shares Outstanding | 159.8M | 163.1M | 162.1M | 163.1M | 162.7M |
| Diluted Shares Outstanding | 159.8M | 163.1M | 162.1M | 163.1M | 162.7M |
| Profitability Metrics | |||||
| EBITDA | — | 59.0M | 108.4M | 168.6M | 209.5M |
| D&A | — | 61.1M | 69.8M | 80.3M | 78.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026